Suggested Remit: To appraise the clinical and cost effectiveness of sapropterin within its marketing authorisation for treating phenylketonuria
Following a challenge to the decision to review sapropterin for treating phenylketonuria through the technology appraisal programme, NICE has made the exceptional decision to pause the appraisal at this point and ask the topic selection decision making panel to reconsider whether this topic is suitable for the NICE highly specialised technologies or technology appraisal programme. After this a formal referral will be required from the Minister to determine the process under which sapropterin will be assessed. An update will be provided once a formal referral is received.
 
Status Suspended
Process STA 2018
ID number 1475

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 February 2019 Suspended, Following a challenge to the decision to review sapropterin for treating phenylketonuria through the technology appraisal programme, NICE has made the exceptional decision to pause the appraisal at this point and ask the topic selection decision making panel to reconsider whether this topic is suitable for the NICE highly specialised technologies or technology appraisal programme. After this a formal referral will be required from the Minister to determine the process under which sapropterin will be assessed. An update will be provided once a formal referral is received.
16 October 2018 Invitation to participate
09 October 2018 In progress, Topic referred
13 August 2018 - 10 September 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance